13
May
2020
If Trikafta Isn’t Good Enough for ICER, What Drug Is?
Last week ICER released a report concluding that Vertex’s groundbreaking triple-combination cystic fibrosis (CF) drug, Trikafta, is too expensive for the value it provides to patients. By all scientific and clinical standards—including ICER’s own—Trikafta, a novel combination of a CFTR potentiator and two correctors, is a transformative drug. It compensates for a mutation present in 90% of all CF patients, turning a disease...Read More
17
Feb
2020
As Scientists, It’s Our Duty to Speak Up as the 2020 Election Nears
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.